Cullgen’s pipeline of targeted protein degraders feature three programs that are in human clinical development and address several important therapeutic areas including pain and oncology. Our most advanced degrader program is a pan-TRK degrader that recently completed  a phase I clinical trial for the treatment of acute and chronic pain.